BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Covid How'. (Return)

Yahoo BusinessOct 26, 2020
Good Entry Point for Gilead Sciences (GILD)? Not Just Yet, Says Analyst
Gilead Sciences (GILD) notched a first last week, when its antiviral coronavirus treatment Veklury (remdesivir) received full FDA approval.The treatment had previously been granted emergency use authorization (EUA), but the complete go ahead from the regulatory body makes it the first treatment to make it across the finish line.However, ultimately, Raymond James analyst Steven Seedhouse does not expect the long-awaited approval to have the impact investors might hope for."The formal FDA approval doesn't change our estimates or outlook for remdesivir, given it has already been branded standard-of-care prior to formal approval," Seedhouse said. "But the label and approval is pretty much a best case for GILD vs. what could have been post SOLIDARITY results. It remains unclear how frequently Veklury actually gets used going forward. Especially given the myriad post marketing requirements including requirement to more rigorously look at viral shedding and viral load in all samples collected and submit to FDA (which we suspect will show limited or no effect and thus offer no mechanistic support)."Gilead stock has been on a roller coaster ride in 2020. Shares rose dramatically following the pandemic's onset, as hopes were pinned on remdesivir to play its part in the battle against COVID-19.However, questions about the drug's commercial potential and contradicting clinical results, amongst other issues, have sent the share price on a downward trajectory since April's yearly peak.Earlier this month,

KiplingerOct 12, 2020
10 Best European Stocks for an Income-Rich Recovery
Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best European stocks are one such store of value-priced diversification.

U.S. stocks are closing on all-time highs yet again, and the S&P 500 is trading at nearly 23 times trailing 12-month earnings. Foreign stocks are a bargain by comparison, trading at a P/E of less than 18, according to Morningstar.

Value is just one of many arguments in favor of international investing. For years, wealth advisors have told clients to invest a portion of their funds overseas to diversify portfolios and mitigate risk.

This advice is particularly timely now given that some European countries are recovering more quickly from COVID-19 than the U.S. In addition to individual-country measures, the European Union passed an $880 billion stimulus package; the U.S. continues to argue about its own follow-up plan.

Economists also anticipate a bigger GDP recovery for Europe next year, with growth pegged as high as 6% versus sub-5% growth for the U.S. Another factor is the present weakness of the U.S. dollar, which makes European stocks and other foreign equities more attractive for U.S. investors.  

Here are 10 of the best European stocks you can buy right now. They offer a combination of growth prospects and value. Better still, many of them offer healthy dividend yields, and some are even members of the European Dividend Aristocrats.

SEE MORE 65 Best Dividend Stocks You Can Count On in 2020

TRENDING TAGS
StocksCases Surge Virus making biggest
Stockmarket cases Today futures Surge
Casescoronavirus Dow points Surge Record
Coronaviruscases Dow high points latest
COVID-19Cases Surge Dow points Testing
Dowpoints cases coronavirus Down record
marketStock cases futures Stocks Dow
hitCoronavirus cases record high stocks
AntIPO Group raise Jack Ma
EarningsCall Transcript Q3 Inc Beat

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC